Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 113Colorectal Neoplasms 73Stomach Neoplasms 48Pancreatic Neoplasms 45Rectal Neoplasms 40Neoplasms 29Neoplasm Metastasis 29Colonic Neoplasms 18Esophageal Neoplasms 16Triple Negative Breast Neoplasms 13Adenocarcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 9Bile Duct Neoplasms 8Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Liver Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Cholangiocarcinoma 5Breast Neoplasms, Male 5Somatostatinoma 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Gastrointestinal Neoplasms 3Gastrinoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Solid Tumor 2

Interventions

Gemcitabine 4Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3PEGPH20 2napabucasin 1folfirinox 1Radiotherapy 1Enoxaparin 1Dexamethasone 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Pancreatic Ductal × Capecitabine × Clear all
NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡